Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.37 |
| ▸ | XIAP | P98170 | 6/20 | 0.36 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | CASP4 | P49662 | 1/20 | 0.34 |
| ▸ | CASP5 | P51878 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CASP9 | P55211 | 1/20 | 0.34 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.34 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137242 | 1.00 | ELANE (0.39) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20151699 | 1.00 | ELANE (0.39) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20137203 | 0.94 | AGTR2 (0.40) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20152040 | 0.94 | AGTR2 (0.40) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20137204 | 0.94 | AGTR2 (0.40) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20137192 | 0.94 | AGTR2 (0.40) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20137190 | 0.94 | AGTR2 (0.40) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20151666 | 0.87 | ABCB1 (0.35) | ELANEAGTR2XIAPBIRC3BIRC2 | |
| SCHEMBL20148215 | 0.85 | XIAP (0.56) | XIAPBIRC3BIRC2 | |
| SCHEMBL12442625 | 0.82 | MMP2 (0.40) | ELANEXIAPBIRC3BIRC2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286169-B1 | PROTAC COMPOUNDS MODULATING RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3286169-B1 | PROTAC COMPOUNDS MODULATING RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10435391-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-10435391-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134688-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435391-B2 | Compounds | RIPK2, RIPK1, RIPK4 | ELANE 1482/4885AGTR2 3075/4885XIAP 10/4885 |
| US-20180134688-A1 | NOVEL COMPOUNDS | RIPK2, RIPK1, RIPK4 | ELANE 1327/4885AGTR2 2972/4885XIAP 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.